ACHC vs DAWN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACHC's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining earnings, and high leverage. The absence of an Altman Z-Score and negative ROE (-40.96%) raise significant bankruptcy risk concerns. Despite a modest forward P/E of 14.03 and strong recent earnings surprises, the company's negative profit margin (-33.29%) and massive year-over-year EPS decline (-89.1%) undermine its fundamentals. The stock's 5-year price drop of 61.4% and lack of dividend support further signal investor skepticism. Analysts recommend 'buy' but with limited conviction, as the underlying financial health remains fragile.
DAWN shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ACHC vs DAWN: Head-to-Head Comparison
This page compares Acadia Healthcare Company, Inc. (ACHC) and Day One Biopharmaceuticals, Inc. (DAWN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.